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Left Ventricular Ejection
Fraction in Addition to
N-Terminal Pro–B-Type
Natriuretic Peptide for
Risk Stratification in the
Ambulant Elderly
Get the Picture . . . or Not?*
A. Mark Richards, MD
Christchurch, New Zealand; and Singapore
Life-time risks of heart failure (HF) and/or cardiovascular
death (CVD) in the elderly are high, and strategies for
accurate risk stratification are needed. In this issue of the
Journal, deFilippi et al. (1) report from the CHS (Cardio-
vascular Health Study) on an assessment of N-terminal
pro–B-type natriuretic peptide (NT-proBNP) and echocar-
diographic left ventricular ejection fraction (LVEF) in
screening for risk of subsequent new-onset HF and CVD in
ambulant elderly patients. In established cardiac disease,
both indicators are independent predictors of adverse car-
diovascular outcomes and, in combination, improve risk
stratification (2). In contrast, the authors conclude that, in
this initially HF-free population, LVEF did not reliably add
to risk stratification beyond information provided from
NT-proBNP levels.
See page 1497
The CHS recruited 5,888 independent adults (65 years
of age) from 4 communities. Those with known HF were
excluded, and analyses were conducted on 4,137 participants
with left ventricular systolic function by using echocardiog-
raphy and assay of NT-proBNP. The population was
divided into those with NT-proBNP levels190 and190
pg/ml. LVEF was divided into 2 groups (normal 55%;
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research grants from Roche Diagnostics.bnormal 55%). Because NT-proBNP exceeded 190
g/ml in 29.5% and LVEF was abnormal in 7.7%, most
levated NT-proBNP values were not associated with an
bnormal LVEF. Over 10 years of follow-up, 1,112 new-
nset HF events and 893 cardiovascular-related deaths
ccurred.
When indexed to the group with both low-peptide and
ormal LVEF (n  2,783; 67.3%), adjusted hazard ratios
ere progressively higher (1.75, 2.75, and 5.73 for HF and
.68, 1.92, and 2.95 for CVD) in the low-peptide/low
jection fraction, high-peptide/normal ejection fraction, and
igh-peptide/low ejection fraction groups, respectively.
azard ratios for both endpoints differed significantly
etween the 2 high-peptide groups but not between the 2
roups with peptide levels 190 pg/ml. Both C-statistic
nd net reclassification improvement (NRI) tests showed no
mportant additive value in adding LVEF to NT-proBNP.
he authors comment that 14 participants with elevated
T-proBNP levels would need to be screened to detect 1
atient with subnormal LVEF (45%). The “take-home
essage” offered is “. . . once adjusting for the multiple
omorbidities often present in ambulatory older patients, we
ere unable to demonstrate that an assessment of LVEF
ould further stratify prognosis after measurement of NT-
roBNP. In the presence of an elevated NT-proBNP level
n this population, a tailored approach to cardiac imaging
ppears most appropriate.”
What can we gain from the risk stratification documented
n the current report? The sensitivity and predictive values
f screening tests depend on the threshold values adopted.
sing 190 pg/ml to define elevation of NT-proBNP and
55% to mark abnormal LVEF in the current study, about
ne-half of both endpoints occurred in patients who did not
ross either threshold, so sensitivity is poor. In those in
hom both markers were adverse, 57% incurred HF over 10
ears compared with 21% if neither was positive. The
orresponding figures for CVD were 19.1% and 7.9%. Is
his useful stratification, guiding allocation of patients to
ore or less aggressive surveillance and pharmacotherapy?
t progressively higher threshold values of NT-proBNP,
ndividual risk may become high enough to confidently
andate early and aggressive investigation and treatment.
Lack of prognostic contribution from LVEF reflects the
nability of an infrequent marker to provide much overall
redictive value. Multivariable analysis incorporating NT-
roBNP as a continuous variable and LVEF as a semi-
uantitative variable did support an independent association
f LVEF with outcomes. This finding suggests that given
ufficiently fine-grained data with an objective percent
VEF calculated for each individual rather than use of
road semiquantitative categories, LVEF may have retained
ome independent predictive power. However, retention of
ignificance in multivariable models does not equate to
eaningful clinical value. Assessment of the additive value
f a marker has been strengthened in recent years by the
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tarium, and this tool has been put to good effect by deFilippi
et al. (1) to illustrate convincingly how little LVEF adds
overall to prognostication in the ambulant elderly (3).
Uncommon abnormalities can carry potential prognostic
significance in only a few people.
Self-evidently, LVEF cannot predict HF in the presence
of a preserved ejection fraction (HF-PEF), which is com-
mon in HF occurring in the elderly (4). In this regard, it is
notable that a high proportion of heart failure events in the
report from deFilippi et al. (1) occurred in the presence of a
normal LVEF.
This paper reflects an interesting maturation in our under-
standing of information offered by the circulating B-type
cardiac peptides. Early clinical studies focused on the utility or
otherwise of plasma B peptides in assisting diagnosis of acute
decompensated heart failure and on the ability to detect the
presence of a depressed LVEF (5,6). With successive reports
confirming the relationship of B-type peptides to both short-
and long-term all-cause mortality and cardiovascular outcomes
in both clinic and community, the focus has shifted to defining
the best markers to accurately predict outcomes in specific
settings (7).
Despite undisputed power to independently stratify pa-
tients for risk of important adverse outcomes, knowledge of
elevated NT-proBNP (or B-type natriuretic peptide) levels
in the asymptomatic patient may yet leave us destitute of
any useful response. This contrasts with our response to
knowledge of LVEF because evidence indicates that treat-
ment of asymptomatic reduced LVEF will improve out-
comes (8). There is no analogous evidence connecting
awareness of asymptomatic elevated plasma NT-proBNP/
B-type natriuretic peptide to any specific therapeutic re-
sponse known to alter outcome. Even if such elevations
heighten ability to predict HF-PEF, we have no therapy
proven to improve outlook (9). Furthermore, the association
of NT-proBNP with depressed LVEF remains indisputable
(1,2) and, despite the conclusion of the current paper, this
association will inevitably encourage progression to echo-
cardiography when an elevated NT-proBNP is found in
older ambulant patients. The current report tells us this
approach will have low yield in terms of finding depressed
LVEF, but it also tells us that in 1 in 14 cases when
NT-proBNP exceeds 190 pg/ml, we will miss a reduced
LVEF (45%) by not referring for echocardiography. What
is the clinician to do? Advice to adopt a “tailored approach” is
enigmatic and does not resolve this conundrum.
Echocardiography is noninvasive and informative, reveal-
ing details of structure and function that can never be
elucidated by B-type peptide measurements alone. It would
be helpful to know what proportion of CHS echocardio-
grams revealed any previously undiagnosed cardiac pathol-
ogy (including wall motion abnormalities, left ventricular
hypertrophy, hypertrophic cardiomyopathy, asymptomatic
valve dysfunction, and elevations in pulmonary artery pres-
sure) and their associations with NT-proBNP levels. Aproportion of such findings would warrant surveillance
and/or institution of treatment. Rather than focusing solely
on the ability of echocardiography to provide an LVEF that
turns out to add little beyond NT-proBNP in long-term
prognostication for HF or death, it seems important to
examine the full picture to assess the utility of NT-proBNP
in alerting clinicians to any actionable cardiac abnormality.
Further inspection of the CHS data may provide some
insight into this issue. It is likely NT-proBNP–triggered
echocardiography will reveal a high prevalence of diastolic
dysfunction, but the physician may still be left with no clear
indication for introducing any specific therapy. Given the
accumulating evidence, it is possible we should conduct
controlled therapeutic trials to assess the benefits or other-
wise of introducing treatment to those with predefined
combinations of deranged peptide levels and echocardio-
graphic abnormalities currently associated with poorer prog-
nosis but not yet validated as indications for intervention.
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